Clopidogrel Bisulphate 75 mg + Aspirin 150 mg is a dual antiplatelet therapy (DAPT) formulation designed to prevent blood clot formation in patients at high risk of cardiovascular events. This combination works by inhibiting platelet aggregation through two different mechanisms, thereby reducing the risk of heart attack, stroke, and other thrombotic complications. Clopidogrel belongs to the P2Y12 platelet inhibitor class, while Aspirin is a non-steroidal anti-inflammatory drug (NSAID) with antiplatelet action. Together, they provide synergistic protection against clot formation in patients with coronary artery disease, post-angioplasty, stent placement, unstable angina, and history of myocardial infarction. This combination is commonly prescribed as part of dual antiplatelet therapy after procedures like angioplasty or in acute coronary syndrome management.
